Skip to content

Fetuin-A as a Marker in Obesity and Type 2 Diabetes Mellitus

Study of Using Serum Fetuin-A as a Marker in Obesity and Type 2 Diabetes Mellitus

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04218305
Enrollment
400
Registered
2020-01-06
Start date
2016-01-01
Completion date
2016-03-01
Last updated
2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabete Type 2

Brief summary

The aim of this study is to assess the significance of serum fetuin-A as a marker of obesity and type 2 diabetes mellitus. We used multiple statistical approaches to determine that the fetuin-A level is correlated to body mass index (BMI) as well as random blood sugar in type 2 diabetic patients. Also, we found that there is a Positive correlation between the serum fetuin-A levels and the level of glycosylated hemoglobin (HbA1c) in diabetic patients.

Detailed description

The study was a case-control study. We started the study to be performed on eighty subjects divided into four groups: The first group: include twenty subjects with type 2 diabetes mellitus The second group: include twenty obese subjects whose body mass index is 30 or over The third group: include twenty obese subjects with type 2 diabetes mellitus The fourth group includes twenty apparently healthy subjects as control. In this study, we concluded that: 1. Serum fetuin-A can be used as a biomarker and independent risk factor and marker for diagnosis of DM and DM has a detrimental effect on serum fetuin-A fetuin-A could be of relevance for the development of insulin resistance 2. Higher fetuin-A concentrations were associated with type 2 diabetes and insulin resistance 3. Increased serum fetuin-A levels constitute an independent marker of lipid profile. 4. fetuin-A may play a role in the pathogenesis of T2DM. 5. The inhibition of insulin receptor by fetuin-A may lead to increased lipolysis and efflux of free fatty acids from adipose tissue. This could explain associated dyslipidemia observed in type 2 diabetic patients in the present study. Finally, our finding that high plasma fetuin-A levels predict the incidence of type 2 diabetes independently of other established risk factors supports the hypothesis that fetuin-A may play a role in the development of type 2 diabetes.

Interventions

DIAGNOSTIC_TESTSerum Level Of Fetuin A

Sponsors

Minia University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
45 Years to 60 Years

Inclusion criteria

* • The study included obese and type 2 diabetic patients aged 45-60 years old. and control healthy adult persons

Exclusion criteria

* • Cardiac disease and Hypertensive disease * Respiratory disease * Renal disease * GIT and Liver disease * Rheumatologic disease * Blood disease * Endocrine disease except for type 2 diabetes mellitus * All with a specific therapeutic drug history.

Design outcomes

Primary

MeasureTime frameDescription
1- Study of human serum fetuin-A and whether it is involved in insulin resistanceBaesline2- To assess the significance of serum fetuin-A as a marker in obesity and type 2 diabetes mellitus

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026